Farmacodermias graves

1. Verma R, Vasudevan B, Pragasam V. Severe cutaneous adverse drug reactions. Med J Armed Forces India 2013; 69(4):375–383. doi:10.1016/j.mjafi .2013.01.007

2. Crisafulli G, Franceschini F, Caimmi S, et al. Mild cutaneous reactions to drugs. Acta Biomed 2019; 90(3–S):36–43. doi:10.23750/abm.v90i3-S.8159

3. Holland KE, Soung PJ. Acquired rashes in the older child. In: Kliegman RM, Lye PS, Bordini BJ, Toth H, Basel D, eds. Nelson Pediatric Symptom-based Diagnosis. Philadelphia, PA: Elsevier; 2018:866–896.e2.

4. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010; 5:39. doi:10.1186/1750-1172-5-39

5. Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clin Dermatol 2020; 38(1):94–104. doi:10.1016/j.clindermatol.2019.10.015

6. Hoetzenecker W, Mehra T, Saulite I, et al. Toxic epidermal necrolysis. F1000Res 2016; 5:F1000 Faculty Rev-951 Published 2016 May 20. doi:10.12688/f1000research.7574.1

7. Alvarado SA, Muñoz-Mendoza D, Bahna SL. High-risk drug rashes. Ann Allergy Asthma Immunol 2018; 121(5):552–560. doi:10.1016/j.anai.2018.05.022

8. Zimmerman D, Dang NH. Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): immunologic reactions. Oncologic Critical Care 2019; 267–280. doi:10.1007/978-3-319-74588-6_195

9. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch

10. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115(2):149–153. doi:10.1046/j.1523-1747.2000.00061.x

11. de Prost N, Ingen-Housz-Oro S, Duong TA, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010; 89(1):28–36. doi:10.1097/MD.0b013e3181ca4290

12. Ye LP, Zhang C, Zhu QX. The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis. PLoS One 2016; 11(11):e0167120. doi:10.1371/journal.pone.0167120

13. Hsieh MH, Watanabe T, Aihara M. Recent dermatological treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan. Front Med (Lausanne) 2021; 8:636924. doi:10.3389/fmed.2021.636924

14. Kumar R, Das A, Das S. Management of Stevens-Johnson syndrome- toxic epidermal necrolysis: looking beyond guidelines! Indian J Dermatol 2018; 63(2):117–124. doi:10.4103/ijd.IJD_583_17

15. Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med 2008; 40(2):129–138. doi:10.1080/07853890701753664

16. Soria A, Bernier C, Veyrac G, Barbaud A, Puymirat E, Milpied B. Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study. J Am Acad Dermatol 2020; 82(3):606–611. doi:10.1016/j.jaad.2019.09.036

17. Lee HY, Tay LK, Thirumoorthy T, Pang SM. Cutaneous adverse drug reactions in hospitalised patients. Singapore Med J 2010; 51(10):767–774. pmid:21103811

18. Mori F, Caffarelli C, Caimmi S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) in children. Acta Biomed 2019; 90(3–S):66–79. doi:10.23750/abm.v90i3-S.8167

19. De A, Rajagopalan M, Sarda A, Das S, Biswas P. Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature. Indian J Dermatol 2018; 63(1):30–40. doi:10.4103/ijd.IJD_582_17